Study Status: ACTIVE_NOT_RECRUITING
Recruit Status: ACTIVE_NOT_RECRUITING
Study Type: OBSERVATIONAL
Official Title: A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer(mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in F
Brief Summary:
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer is one of the most common cancers in men.
The prostate is a gland in the male body that helps make semen.
Most prostate cancers need male sex hormones, such as testosterone, to grow.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels is known as "castration-resistant".
Metastatic cancer is a cancer that has spread to other parts of the body.
This is a real-world study, not a clinical trial.
This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment.
In this study, researchers will use information from the Flatiron Electronic Health Record (EHR) database.
The study will include patients' information from the database for men who:
Men who are part of this study will receive enzalutamide or abiraterone as part of their usual treatment for mCRPC.
We will compare the following between men receiving enzalutamide and men receiving abiraterone: